Both Ra Pharmaceuticals Inc. (NASDAQ:RARX) and Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ra Pharmaceuticals Inc.||25||552.89||N/A||-1.92||0.00|
|Diffusion Pharmaceuticals Inc.||3||0.00||N/A||-5.38||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 has Ra Pharmaceuticals Inc. and Diffusion Pharmaceuticals Inc.’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Ra Pharmaceuticals Inc.||0.00%||-47%||-43.5%|
|Diffusion Pharmaceuticals Inc.||0.00%||-92.8%||-81.2%|
The current Quick Ratio of Ra Pharmaceuticals Inc. is 20.1 while its Current Ratio is 20.1. Meanwhile, Diffusion Pharmaceuticals Inc. has a Current Ratio of 5.3 while its Quick Ratio is 5.3. Ra Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Diffusion Pharmaceuticals Inc.
The table delivered features the ratings and recommendations for Ra Pharmaceuticals Inc. and Diffusion Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ra Pharmaceuticals Inc.||0||0||2||3.00|
|Diffusion Pharmaceuticals Inc.||0||0||0||0.00|
The upside potential is 64.57% for Ra Pharmaceuticals Inc. with consensus price target of $48.5.
Insider & Institutional Ownership
Institutional investors owned 99.9% of Ra Pharmaceuticals Inc. shares and 30.6% of Diffusion Pharmaceuticals Inc. shares. 0.6% are Ra Pharmaceuticals Inc.’s share owned by insiders. Comparatively, Diffusion Pharmaceuticals Inc. has 0.1% of it’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ra Pharmaceuticals Inc.||-0.76%||2.81%||56.87%||72.27%||210.02%||87.03%|
|Diffusion Pharmaceuticals Inc.||1.35%||-19.86%||-26.62%||5.61%||-57.49%||13.57%|
For the past year Ra Pharmaceuticals Inc.’s stock price has bigger growth than Diffusion Pharmaceuticals Inc.
Ra Pharmaceuticals Inc. beats on 8 of the 8 factors Diffusion Pharmaceuticals Inc.
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companyÂ’s preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM. Diffusion Pharmaceuticals Inc. is headquartered in Charlottesville, Virginia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.